Glick, B., Lain, E., Lin, T. and Israel, R. (2019) “Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast)”, SKIN The Journal of Cutaneous Medicine, 3, p. S30. doi: 10.25251/skin.3.supp.30.